IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Purchases 50,000 Shares

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin acquired 50,000 shares of IRIDEX stock in a transaction that occurred on Wednesday, May 14th. The shares were purchased at an average cost of $1.10 per share, with a total value of $55,000.00. Following the purchase, the insider owned 298,348 shares of the company’s stock, valued at $328,182.80. This represents a 20.13% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

IRIDEX Price Performance

NASDAQ IRIX opened at $0.90 on Friday. IRIDEX Corporation has a 1 year low of $0.61 and a 1 year high of $1.65. The stock has a market capitalization of $15.78 million, a PE ratio of -4.49 and a beta of 0.67. The company’s 50 day simple moving average is $0.73 and its two-hundred day simple moving average is $0.95.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The firm had revenue of $12.57 million for the quarter, compared to analysts’ expectations of $13.59 million. On average, research analysts anticipate that IRIDEX Corporation will post -0.12 EPS for the current year.

Hedge Funds Weigh In On IRIDEX

Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp purchased a new stake in shares of IRIDEX during the 2nd quarter valued at $29,000. Diversify Advisory Services LLC purchased a new position in IRIDEX in the second quarter worth $30,000. Diversify Wealth Management LLC bought a new position in IRIDEX in the first quarter valued at $35,000. United Capital Financial Advisors LLC bought a new position in IRIDEX in the second quarter valued at $41,000. Finally, Thompson Davis & CO. Inc. raised its position in IRIDEX by 66.5% during the first quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 18,944 shares in the last quarter. Institutional investors own 20.10% of the company’s stock.

Key IRIDEX News

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
• Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
• Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
• Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $3.00.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.